Deka Biosciences

[December 2021]


Deka Bioscience is a three-year-old biotechnology R&D startup focused on the discovery and development of the next generation of cytokine therapies to treat devastating diseases such as cancer, Crohn’s, sepsis, psoriasis, and rheumatoid arthritis. Co-founder & Chief Business Officer Pavel Khrimian explains that Deka used nature as its guide in designing an enhanced manufacturing scaffold platform that extends half-life, targets specific tissues, and delivers disease controlling dual cytokine (Diakine™) combinations directly into affected tissues. Responses to a given cytokine vary. Deka has also developed disease-specific assays to determine who will best respond and benefit from the Diakine therapies.

eLabNext provides a One-Stop Solution for Deka Bioscience

ChallengeSo Many Challenges, So Little Time

SolutioneLabNext Stands Out for Research and Development and Day-to-Day Operations

ResultAll Challenges Met in a Single Stroke with eLabNext


By implementing eLab, Deka Bioscience was able to streamline its production and testing processes as well as its data management systems.

Pavel Khrimian, Co-founder & CEO


Download PDF


< Back to overview


Get started with eLabNext today

Personal demo, free lab workflow assessment, and friendly expert guidance.

© 2022 eLabNext